Vés al contingut

Nanopartícules Farmacocinètiques

El grup de Nanopartícules Farmacocinètiques del Vall d’Hebron Institut de Recerca es centra en la síntesi, caracterització i aplicacions de nanopartícules inorgàniques en el camp de la medicina. En controlar el nucli inorgànic (mida, estructura i forma) i la unió de molècules a la seva superfície, dissenyem nanopartícules que interactuen amb els sistemes biològics d'una manera específica. També posem especial èmfasi en la seguretat, viabilitat, ampliació, aplicabilitat i altres aspectes del disseny de nanopartícules per a la medicina.

El nostre grup està dirigit pel professor Víctor Puntes, qui té una Càtedra d'Investigació ICREA. Atès que una gran part del nostre treball exigeix una experiència altament multidisciplinària, mantenim col·laboracions amb físics, biòlegs, immunòlegs, oncòlegs i altres, d'Europa, la Xina i els EUA. El treball del grup ha donat lloc a diverses patents i a la creació d’empreses derivades (spin-off) com Nanotargeting i Applied nanoparticles.

Equip

Alex Escarrà Pont

Alex Escarrà Pont

Tècnic de recerca
Nanopartícules farmacocinètiques
Llegir més
Joana Ramis Garcia

Joana Ramis Garcia

Investigador predoctoral
Nanopartícules farmacocinètiques
Llegir més
Lena Nerea Montaña Ernst

Lena Nerea Montaña Ernst

Investigador predoctoral
Nanopartícules farmacocinètiques
Llegir més
Muriel Freixanet Gustà

Muriel Freixanet Gustà

Investigador predoctoral
Nanopartícules farmacocinètiques
Llegir més
Ramon Gonzalez Rioja

Ramon Gonzalez Rioja

Tècnic de recerca
Nanopartícules farmacocinètiques
Llegir més
Victor Franco Puntes

Victor Franco Puntes

Cap de grup
Nanopartícules farmacocinètiques
Llegir més
Alex Escarrà Pont

Alex Escarrà Pont

Tècnic de recerca
Nanopartícules farmacocinètiques
Llegir més
Joana Ramis Garcia

Joana Ramis Garcia

Investigador predoctoral
Nanopartícules farmacocinètiques
Llegir més
Lena Nerea Montaña Ernst

Lena Nerea Montaña Ernst

Investigador predoctoral
Nanopartícules farmacocinètiques
Llegir més
Muriel Freixanet Gustà

Muriel Freixanet Gustà

Investigador predoctoral
Nanopartícules farmacocinètiques
Llegir més
Ramon Gonzalez Rioja

Ramon Gonzalez Rioja

Tècnic de recerca
Nanopartícules farmacocinètiques
Llegir més
Victor Franco Puntes

Victor Franco Puntes

Cap de grup
Nanopartícules farmacocinètiques
Llegir més

Línies de recerca

Design of nanoparticles for useful applications

Getting advantages from the accumulated experience, I will study the most problematic points related to the growth of multi-component materials and hollow structures. We are preparing complex multifunctional environment responsive NPs comprising different families: i) metallic, ii) metal oxide, iii) semiconductor and iv) oxides of semiconductor. Beyond synthesis, I will focus on the precise characterization of the obtained NPs in terms of their reactivity and physico-chemical properties to precisely correlate morphology with activity. The synthesis of advanced NPs will be carry out, primarily, following seeding-growth approaches or by combining the simultaneous or sequential injection of precursor solutions, surfactant mixtures. The temperature of the solution will be adjusted in order to kinetically control the formation of the NPs and reaction times will be controlled to induce digestion processes and re-crystallizations/controlled sintering when required.  I will use mixtures of surfactants or reducing agents and coordinating complexes under controlled atmospheres, intending to independently modify the solubility of the monomer, the nucleation radii, the growing rate and the morphology of the growing structure (by stabilizing different crystals phases and therefore lowering their energy and accelerating selected competing reactions). Hollow metal structures will be synthesized following a multi-step procedure. In the first step, Ag nanocubes are synthesized by known techniques (such as polyol synthesis). Polymetallic hollow NPs with very different morphology  and composition, will be obtained by the simultaneous or sequential action of galvanic replacement and the Kirkendall effect in order to control the number and morphology of void spaces inside a single NP, and the chemical transformation of NPs such as cation release/exchange. This allows the production of, among other, monodisperse single- and double-walled nanoboxes or noble metal fullerenes, in high yields and scalable synthesis.


a. APPLICATION ON MEDICINE.

Nanotechnology’s ability to shape matter at the scale of molecules is opening the door to a new generation of diagnostics, imaging agents and drugs/therapies for detecting and treating disease. But perhaps more important,  it is allowing to combine a series of advances, creating nanosized particles that may for example contain drugs designed to kill damaged cells together with targeting compounds designed to home-in on malignancies, and imaging agents designed to light up even the earliest stage of disease. For example NPs are perfect candidates to be used in anticancer therapy since they showed passive accumulation in solid tumours due to the Enhanced Permeation and Retention effect (EPR). Is in this context that nanotechnology emerges as a “disruptive technology” with a great potential to contribute to improve treatment by generating new diagnostic and therapeutic products. Its fields of action can be classified in diagnosis, imaging, drug delivery, hyperthermia, theranostics, the simultaneous diagnosis and therapy, and therapy monitoring.


It has been acknowledged that one of the most promising societal impacts of nanotechnology is in the area of nanomedicine. Personalized health care, rational drug design and targeted drug delivery are some of the proposed benefits of a nanomedicine-based approach to therapy. On this subject, my lines of work are: i) Nanooncology, the use of nanoparticles for diagnosis and treatment of cancer. Here I am developing NP-Biomolecule (as AuNP-Antibody) for detection (as lung cancer in breath or circulating cancer cells) and AuNP and Fe3O4 NP for diagnosis/imaging. I continue my work carrying antitumoral drugs with AuNPs (as cisplatin, oxaliplatin, carboplatin, doxorubicin, and sorafenib) and their use as radiotherapy enhancers or hyperthermia agents. ii) Immunology. Significantly important is the interaction of NPs with the immune system. Because one cannot put stuff inside the body without asking the immune system for permission, I am studying the effect of NP on antigen presentation, to then avoid immune detection (for a drug delivery vehicle) or design prophylactic and therapeutic vaccines (for molecular scaffolds). This includes as much AuNPs decorated with antigens as redox active anti-inflammatory CeO2 NPs. iii) Antimicrobial NPs. The emergence of antibiotic resistant strains of common pathogens is a major threat to health and is already putting tremendous pressure on health services worldwide. It has been shown that positive (cationic) nanoparticles show toxic effects to prokaryote, as defensines do. Also, silver, iron or cerium NPs, yield ions that are toxic for prokaryote cells (but well tolerated in eukaryote), acting as disinfectant and bacteriostatic agents. iv) Nanosafety: the prevention of unwanted effects produced by nanoparticles. This is one of our core-expertise areas and I have been working on it, developing NP models for toxicity and ecotoxicity testing, since FP06. My job is to understand which features of NPs poses health threats and then modify the NPs and the way they are used, to avoid the related hazards or exposure (risks) while maintaining the parental desired NP properties.


All this efforts have been translated into the creation of a spin-off company to exploit this knowledge: Nanotargeting (www.nanotargeeting.com), who is actually performing the regulatory preclinical studies and preparing the phase I clinical trials of Aurocis (cisplatin bounded AuNPs).



b. APPLICATION ON ENERGY.

We are facing energy and environmental threats that challenge our world: decrease/consumption of the fossil fuel reserves, global increase in energy demand, increasing pollution and the need to improve the processing of organic waste into a sustainable waste management, since damage to the environment is sooner or later translated into an energy cost. I am working on the design of advanced catalyst (multimetallic and heterodimer NPs) that are able to improve energy-chemical processes. Interestingly, energy harvesting and energy transfer processes are based on physic-chemical principles (electromagnetism) at the scale of few nm, from photosynthesis to electrical transport. I am also working on the design of a new generation of NPs for the production of hydrogen (with CdSe-Pt NPs) for reduction process and transform biomass and produce biofuels. Also I work on the use of iron oxide NPs to boost Biogas production thanks to the fact that iron ions are essential for the bacterial consortia responsible for the degradation and transformation of organic matter into methane. Our approach consists on the use of small concentrations of iron oxide nanoparticles designed and functionalized such that they progressively dispensing active iron ions at the necessary dose (not too low, not too high) for the bacteria, in analogy to sustained drug delivery, boosting methane production up to 300%. This work has been patent and it has received funds from the Bill and Melinda Gates foundation. This project has been granted the second SEGIB international prize and received support from the Programa Emprendedores of the REPSOL foundation leading to the creation of a Spin-Off, Applied Nanoparticles, dedicated to nanotechnology and energy/environment solutions which has, among other, the mission to exploit our Biogas enhanced production patent. I would like to stress that to me energy and environment are closely linked, while indeed, health and environment, are also extremely connected, since the health of the environment determine our morbidity. Regarding environment we address two issues, environmental toxicity of NPs and environmental remediation with NPs. I also focus on the electrochemical oxidation of molecules with our hollow Pt NPs where we are observing also important reactivity (and efficiency) boosts. Finally, I started in collaboration with the chemical engineering department of the UAB, with funding from the Fundación Ramón Areces, the study of nanostructures for the absorption of CO2, in such a way that in the future, the photocatalysis will reduce CO2 to other C species (CO, CH4, CH3OH, CHOOH) and it will be oxydized to recover energy and absorbed to avoid emissions and be transformed into a raw material in a close carbon cycle (note that 75% of south Africa gasoline is synthetic).


My work has position me as a privileged observer of the development of nanotechnology allowing me to advise and communicate to a broad audience. This is translated in participating as Project (e.g.: serenade-labex) or Industry (Nanonica) Scientific Advisor or communicating Science to Society, I am specially proud about the ebook “Nanoparticles before Nanotechnology” with more than 14.000 downloads. Also, the  reporting of my activities in international media, as the BBC or The Guardian also indicates the societal the impact of my work.

IP: Victor Franco Puntes

Projectes

Sol·licitud i-PFIS

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà, Miriam Álvarez Rollan, Miriam Izquierdo Sans
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 82400
Referència: IFI17/00052
Durada: 01/01/2018 - 31/05/2022

Developing multimodal platforms for cancer treatment

IP: Victor Franco Puntes
Col·laboradors: Lena Nerea Montaña Ernst, Miriam Izquierdo Sans
Entitat finançadora: Fundació Institut de Recerca HUVH
Finançament: 47268
Referència: 2018/VHIR/2018/LENA MONTAÑA
Durada: 03/05/2019 - 02/05/2022

Antioxidant and antiinflammatory therapy for the treatment of preeclampsia

IP: Victor Franco Puntes
Col·laboradors: Joana Ramis Garcia
Entitat finançadora: Generalitat de Catalunya - Departament de Salut
Finançament: 89693.23
Referència: SLT017/20/000182
Durada: 14/07/2021 - 31/12/2024

Sol·licitut d'estada post-doctoral en

IP: Victor Franco Puntes
Col·laboradors: Miriam Álvarez Rollan
Entitat finançadora: AGAUR
Finançament: 48896.04
Referència: 2016 BP 00350
Durada: 01/10/2019 - 31/03/2021

Sol·licitud i-PFIS

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà, Miriam Álvarez Rollan, Miriam Izquierdo Sans
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 82400
Referència: IFI17/00052
Durada: 01/01/2018 - 31/05/2022

Developing multimodal platforms for cancer treatment

IP: Victor Franco Puntes
Col·laboradors: Lena Nerea Montaña Ernst, Miriam Izquierdo Sans
Entitat finançadora: Fundació Institut de Recerca HUVH
Finançament: 47268
Referència: 2018/VHIR/2018/LENA MONTAÑA
Durada: 03/05/2019 - 02/05/2022

Development of a universal platform for genetic material delivery

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà, Miriam Izquierdo Sans
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 13800
Referència: MV20/00071
Durada: 01/02/2021 - 31/05/2021

Sol·licitut d'estada post-doctoral en

IP: Victor Franco Puntes
Col·laboradors: Miriam Álvarez Rollan
Entitat finançadora: AGAUR
Finançament: 48896.04
Referència: 2016 BP 00350
Durada: 01/10/2019 - 31/03/2021

Sol·licitud i-PFIS

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà, Miriam Álvarez Rollan, Miriam Izquierdo Sans
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 82400
Referència: IFI17/00052
Durada: 01/01/2018 - 31/05/2022

Developing multimodal platforms for cancer treatment

IP: Victor Franco Puntes
Col·laboradors: Lena Nerea Montaña Ernst, Miriam Izquierdo Sans
Entitat finançadora: Fundació Institut de Recerca HUVH
Finançament: 47268
Referència: 2018/VHIR/2018/LENA MONTAÑA
Durada: 03/05/2019 - 02/05/2022

INNOCENT: Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 96049.8
Referència: AC16/00053
Durada: 01/01/2017 - 30/06/2021

Sol·licitut d'estada post-doctoral en

IP: Victor Franco Puntes
Col·laboradors: Miriam Álvarez Rollan
Entitat finançadora: AGAUR
Finançament: 48896.04
Referència: 2016 BP 00350
Durada: 01/10/2019 - 31/03/2021

Sol·licitud i-PFIS

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà, Miriam Álvarez Rollan, Miriam Izquierdo Sans
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 82400
Referència: IFI17/00052
Durada: 01/01/2018 - 31/05/2022

Developing multimodal platforms for cancer treatment

IP: Victor Franco Puntes
Col·laboradors: Lena Nerea Montaña Ernst, Miriam Izquierdo Sans
Entitat finançadora: Fundació Institut de Recerca HUVH
Finançament: 47268
Referència: 2018/VHIR/2018/LENA MONTAÑA
Durada: 03/05/2019 - 02/05/2022

INNOCENT: Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 96049.8
Referència: AC16/00053
Durada: 01/01/2017 - 30/06/2021

NanoFarmacoCinètica: Determinació de les respostes fisicoquímiques dels nanomaterials en diferents medis fisiològics i la seva evolució en l’organisme, per posibilitar el desenvolupament de la nanomedicina.

IP: Victor Franco Puntes
Col·laboradors: Miriam Álvarez Rollan
Entitat finançadora: Generalitat de Catalunya - Departament de Salut
Finançament: 103604.66
Referència: SLT002/16/00312
Durada: 06/04/2017 - 31/12/2018

Sol·licitud Anna García a les beques Juan de la Cierva Formación

IP: Victor Franco Puntes
Col·laboradors: Miriam Álvarez Rollan, Miriam Izquierdo Sans
Entitat finançadora: Ministerio Economía, Industria y Competitividad
Finançament: 50000
Referència: FJCI-2015-26832
Durada: 01/12/2016 - 30/11/2018

Sol·licitud i-PFIS

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà, Miriam Álvarez Rollan, Miriam Izquierdo Sans
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 82400
Referència: IFI17/00052
Durada: 01/01/2018 - 31/05/2022

INNOCENT: Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy

IP: Victor Franco Puntes
Col·laboradors: Muriel Freixanet Gustà
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 96049.8
Referència: AC16/00053
Durada: 01/01/2017 - 30/06/2021

NanoFarmacoCinètica: Determinació de les respostes fisicoquímiques dels nanomaterials en diferents medis fisiològics i la seva evolució en l’organisme, per posibilitar el desenvolupament de la nanomedicina.

IP: Victor Franco Puntes
Col·laboradors: Miriam Álvarez Rollan
Entitat finançadora: Generalitat de Catalunya - Departament de Salut
Finançament: 103604.66
Referència: SLT002/16/00312
Durada: 06/04/2017 - 31/12/2018

Sol·licitud Anna García a les beques Juan de la Cierva Formación

IP: Victor Franco Puntes
Col·laboradors: Miriam Álvarez Rollan, Miriam Izquierdo Sans
Entitat finançadora: Ministerio Economía, Industria y Competitividad
Finançament: 50000
Referència: FJCI-2015-26832
Durada: 01/12/2016 - 30/11/2018

Project acronym: GUIDEnano Grant agreement no: 604387

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 289137.26
Referència: GUIDENANO_FP7NMP2013
Durada: 01/11/2013 - 30/04/2017

Project acronym: FutureNanoNeeds Project full title: " Framework to respond to regulatory needs of future nanomaterials and markets " Grant agreement no: 604602

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 295904.6
Referència: FUTURENANONEEDS_FP7NMP2013
Durada: 01/01/2014 - 31/12/2017

Sol·licitud Anna García a les beques Juan de la Cierva Formación

IP: Victor Franco Puntes
Col·laboradors: Miriam Álvarez Rollan, Miriam Izquierdo Sans
Entitat finançadora: Ministerio Economía, Industria y Competitividad
Finançament: 50000
Referència: FJCI-2015-26832
Durada: 01/12/2016 - 30/11/2018

Project acronym: GUIDEnano Grant agreement no: 604387

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 289137.26
Referència: GUIDENANO_FP7NMP2013
Durada: 01/11/2013 - 30/04/2017

Project acronym: FutureNanoNeeds Project full title: " Framework to respond to regulatory needs of future nanomaterials and markets " Grant agreement no: 604602

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 295904.6
Referència: FUTURENANONEEDS_FP7NMP2013
Durada: 01/01/2014 - 31/12/2017

Project acronym: GUIDEnano Grant agreement no: 604387

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 289137.26
Referència: GUIDENANO_FP7NMP2013
Durada: 01/11/2013 - 30/04/2017

Project acronym: FutureNanoNeeds Project full title: " Framework to respond to regulatory needs of future nanomaterials and markets " Grant agreement no: 604602

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 295904.6
Referència: FUTURENANONEEDS_FP7NMP2013
Durada: 01/01/2014 - 31/12/2017

Project acronym: GUIDEnano Grant agreement no: 604387

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 289137.26
Referència: GUIDENANO_FP7NMP2013
Durada: 01/11/2013 - 30/04/2017

Project acronym: FutureNanoNeeds Project full title: " Framework to respond to regulatory needs of future nanomaterials and markets " Grant agreement no: 604602

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 295904.6
Referència: FUTURENANONEEDS_FP7NMP2013
Durada: 01/01/2014 - 31/12/2017

Project acronym: GUIDEnano Grant agreement no: 604387

IP: Victor Franco Puntes
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 289137.26
Referència: GUIDENANO_FP7NMP2013
Durada: 01/11/2013 - 30/04/2017

Publicacions

Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro-In Vivo Correlation.

PMID: 35159859
Revista: Nanomaterials
Any: 2022
Referència: Nanomaterials (Basel). 2022 Feb 1;12(3). pii: nano12030511. doi: 10.3390/nano12030511.
Factor d'impacte: 5.076
Tipus de publicació: Article en revista internacional
Autors: Manova, Alena; Bastus, Neus G; Moriones, Oscar H; Kohl, Yvonne; Dusinska, Maria; Runden-Pran, Elise; Puntes, Victor; Nelson, Andrew; Gabelova, Alena; Simon, Peter et al.
DOI: 10.3390/nano12030511

How Does Immunomodulatory Nanoceria Work? ROS and Immunometabolism.

PMID: 35401546
Revista: Frontiers in Immunology
Any: 2022
Referència: Front Immunol. 2022 Mar 17;13:750175. doi: 10.3389/fimmu.2022.750175. eCollection 2022.
Factor d'impacte: 7.561
Tipus de publicació: Article en revista internacional
Autors: Ernst, Lena M, Puntes, Victor et al.
DOI: 10.3389/fimmu.2022.750175

The Interactions between Nanoparticles and the Innate Immune System from a Nanotechnologist Perspective.

PMID: 34835755
Revista: Nanomaterials
Any: 2021
Referència: Nanomaterials (Basel). 2021 Nov 6;11(11). pii: nano11112991. doi: 10.3390/nano11112991.
Factor d'impacte: 5.076
Tipus de publicació: Revisió en revista internacional
Autors: Ernst, Lena M, Casals, Eudald, Italiani, Paola, Boraschi, Diana, Puntes, Victor et al.
DOI: 10.3390/nano11112991

Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells.

PMID: 34394703
Revista: Nano Today
Any: 2021
Referència: Nano Today. 2021 Feb;36. doi: 10.1016/j.nantod.2020.101056. Epub 2020 Dec 20.
Factor d'impacte: 20.722
Tipus de publicació: Article en revista internacional
Autors: Buzon, Maria J, Puntes, Victor, Genesca, Meritxell, Astorga-Gamaza, Antonio, Vitali, Michele, Borrajo, Mireya L, Jaime, Carlos, Bastus, Neus, Serra-Peinado, Carla, Luque-Ballesteros, Laura et al.
DOI: 10.1016/j.nantod.2020.101056

Simple spectroscopic determination of the hard protein corona composition in AuNPs: albumin at 75.

PMID: 32692793
Revista: Nanoscale
Any: 2020
Referència: Nanoscale. 2020 Aug 7;12(29):15832-15844. doi: 10.1039/d0nr02379e. Epub 2020 Jul 21.
Factor d'impacte: 6.895
Tipus de publicació: Article en revista internacional
Autors: Vitali, Michele, Casals, Eudald, Canals, Francesc, Colome, Nuria, Puntes, Victor et al.
DOI: 10.1039/d0nr02379e

Ofertes de treball

Lab Technician - Nanoparticle design and pharmacokinetics
Data d'inici:
09/03/2022
Data de finalització:
23/03/2022
Document: Descarrega
Laboratory Technician
Data d'inici:
23/06/2021
Data de finalització:
07/07/2021
Document: Descarrega
Qualified Technician: Design and Pharmacokinetics of Nanoparticles Research Group
Data d'inici:
11/11/2020
Data de finalització:
25/11/2020
Document: Descarrega